Back to Search Start Over

FDA approval summary: vemurafenib for treatment of unresectable or metastatic melanoma with the BRAFV600E mutation

Authors :
Maitreyee Hazarika
Rajeshwari Sridhara
Xiaoping Jiang
Qiang Casey Xu
Whitney S. Helms
Richard Pazdur
Sarah Pope Miksinski
Kun He
Yang-Min Ning
Justin C. Earp
Shenghui Tang
Anne Marie Russell
Qi Liu
John R. Johnson
Amna Ibrahim
Amy E. McKee
W. David McGuinn
Donna Roscoe
Jeanne Fourie Zirkelbach
Geoffrey Kim
Robert Justice
Marc R. Theoret
Source :
Clinical cancer research : an official journal of the American Association for Cancer Research. 20(19)
Publication Year :
2014

Abstract

On August 17, 2011, the U.S. Food and Drug Administration (FDA) approved vemurafenib tablets (Zelboraf, Hoffmann-LaRoche Inc.) for the treatment of patients with unresectable or metastatic melanoma with the BRAFV600E mutation as detected by an FDA-approved test. The cobas 4800 BRAF V600 Mutation Test (Roche Molecular Systems, Inc.) was approved concurrently. An international, multicenter, randomized, open-label trial in 675 previously untreated patients with BRAFV600E mutation–positive unresectable or metastatic melanoma allocated 337 patients to receive vemurafenib, 960 mg orally twice daily, and 338 patients to receive dacarbazine, 1,000 mg/m2 intravenously every 3 weeks. Overall survival was significantly improved in patients receiving vemurafenib [HR, 0.44; 95% confidence interval (CI), 0.33–0.59; P < 0.0001]. Progression-free survival was also significantly improved in patients receiving vemurafenib (HR, 0.26; 95% CI, 0.20–0.33; P < 0.0001). Overall response rates were 48.4% and 5.5% in the vemurafenib and dacarbazine arms, respectively. The most common adverse reactions (≥30%) in patients treated with vemurafenib were arthralgia, rash, alopecia, fatigue, photosensitivity reaction, and nausea. Cutaneous squamous cell carcinomas or keratoacanthomas were detected in approximately 24% of patients treated with vemurafenib. Other adverse reactions included hypersensitivity, Stevens–Johnson syndrome, toxic epidermal necrolysis, uveitis, QT prolongation, and liver enzyme laboratory abnormalities. Clin Cancer Res; 20(19); 4994–5000. ©2014 AACR.

Details

ISSN :
15573265
Volume :
20
Issue :
19
Database :
OpenAIRE
Journal :
Clinical cancer research : an official journal of the American Association for Cancer Research
Accession number :
edsair.doi.dedup.....93089cb9aff87009dfa9d9e17fe66abb